IL-30 (IL27p28) Attenuates Liver Fibrosis Through Inducing NKG2D-Rae1 Interaction Between NKT and Activated Hepatic Stellate Cells in Mice
Open accessAbstract
UNLABELLED: Chronic hepatic diseases, such as cirrhosis, hepatocellular carcinoma, and virus-mediated immunopathogenic infections, affect billions of people worldwide. These diseases commonly initiate with fibrosis. Owing to the various side effects of antifibrotic therapy and the difficulty of diagnosing asymptomatic patients, suitable medication remains a major concern. To overcome this drawback, the use of cytokine-based sustained therapy might be a suitable alternative with minimal side effects. Here, we studied the therapeutic efficacy and potential mechanisms of interleukin (IL)-30 as antifibrosis therapy in murine liver fibrosis models. CCl4 or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) 0.1% (wt/wt) Purina 5015 Chow (LabDiet, St. Louis, MO) was fed for 3 weeks to induce liver fibrosis. Either control vector (pCtr) or pIL30 was injected hydrodynamically once per week. A significant decrease in collagen deposition and reduced expression of alpha-smooth muscle actin (α-SMA) protein indicated that IL-30-based gene therapy dramatically reduced bridging fibrosis that was induced by CCl4 or DDC. Immunophenotyping and knockout studies showed that IL-30 recruits natural-killer-like T (NKT) cells to the liver to remove activated hepatic stellate cells (HSCs) significantly and ameliorate liver fibrosis. Both flow cytometric and antibody-mediated neutralization studies showed that liver NKT cells up-regulate the natural killer group 2, member D (NKG2D) ligand and bind with the NKG2D ligand, retinoic acid early inducible 1 (Rae1), and positively activated HSCs to ameliorate liver fibrosis. Furthermore, adoptive transfer of liver NKT cells in T-cell-deficient mice showed reduction of fibrosis upon IL-30 administration. CONCLUSIONS: Highly target-specific liver NKT cells selectively remove activated HSCs through an NKG2D-Rae1 interaction to ameliorate liver fibrosis after IL-30 treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies in CCl4 and DDC liver fibrosis models have reported that NKT cells can kill activated HSCs through expression of NKG2D.
“Intriguingly, studies in CCl4 and DDC liver fibrosis models have reported that NKT cells can kill activated HSCs through expression of the NK receptor NKG2D, but its relevance to NASH has not been explored (122, 123).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [123]
In specific contexts NK, NKT, and CD8+ T cells all induce HSC apoptosis to attenuate scar deposition.
“In specific contexts NK, NKT, and CD8+ T cells all induce HSC apoptosis to attenuate scar deposition (21, 108, 123).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 44 · Cited by 94
- Authors
- Mitra, A., Satelli, A., Yan, J., Xueqing, X., Gagea, M., Hunter, C. A., Mishra, L., & Li, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of PediatricsThe University of Texas MD Anderson Cancer CenterHouston TX
- University of Pennsylvania (US)
- Corresponding author
- Li, Shulin
- Venue
- Hepatology
- Published
- 2014-10-28
- Volume
- 60
- Issue
- 6
- Pages
- 2027-2039
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC4245364
- OpenAlex
- W2118682137
- Cited by
- 94
- References
- 44
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 13 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 9 · 2017: 7 · 2016: 11 · 2015: 15 · 2014: 1
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA098928)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- IL-27p28, liver fibrosis, NKT cells, hepatic stellate cells, antifibrotic therapy, gene therapy, CCl4-induced fibrosis, collagen deposition, alpha-smooth muscle actin, cytokine therapy
- MeSH terms
- Animals, Carbon Tetrachloride, Drug Evaluation, Preclinical, Female, Interleukins, Liver Cirrhosis, Mice, Inbred C57BL, Pyridines, Nucleocytoplasmic Transport Proteins, Nuclear Matrix-Associated Proteins, Hepatic Stellate Cells, Natural Killer T-Cells, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
